Literature DB >> 1349840

Why haven't we cured multidrug resistant tumors?

J R Murren1, W N Hait.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1349840

Source DB:  PubMed          Journal:  Oncol Res        ISSN： 0965-0407            Impact factor:   5.574


× No keyword cloud information.
  8 in total

1.  Modulation of doxorubicin-toxicity by tamoxifen in multidrug-resistant tumor cells in vitro and in vivo.

Authors:  E Pommerenke; J Mattern; M Volm
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

2.  Glutathione analogues as novel inhibitors of rat and human glutathione S-transferase isoenzymes, as well as of glutathione conjugation in isolated rat hepatocytes and in the rat in vivo.

Authors:  S Ouwerkerk-Mahadevan; J H van Boom; M C Dreef-Tromp; J H Ploemen; D J Meyer; G J Mulder
Journal:  Biochem J       Date:  1995-05-15       Impact factor: 3.857

3.  Novel carbamate analogues of amsacrine with activity against non-cycling murine and human tumour cells.

Authors:  G J Finlay; K M Holdaway; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Sensitivity of K562 human chronic myelogenous leukemia blast cells transfected with a human multidrug resistance cDNA to cytotoxic drugs and differentiating agents.

Authors:  W N Hait; S Choudhury; S Srimatkandada; J R Murren
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

5.  Novobiocin modulates colchicine sensitivity in parental and multidrug-resistant B16 melanoma cells.

Authors:  J Nordenberg; J Kornfeld; L Wasserman; M Shafran; E Halabe; E Beery; O Landau; A Novogrodsky; Y Sidi
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

6.  Vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro.

Authors:  C Etievant; J M Barret; A Kruczynski; D Perrin; B T Hill
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

Review 7.  Role of protein kinases in antitumor drug resistance.

Authors:  H Grunicke; J Hofmann; I Utz; F Uberall
Journal:  Ann Hematol       Date:  1994       Impact factor: 3.673

8.  Secondary combined resistance to the multidrug-resistance-reversing activity of cyclosporin A in the cell line F4-6RADR-CsA.

Authors:  M Dietel; I Herzig; A Reymann; I Brandt; B Schaefer; A Bunge; H J Heidebrecht; A Seidel
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.